Literature DB >> 17020454

Role of cytokines in head and neck squamous cell carcinoma.

Ralph Pries1, Stefan Nitsch, Barbara Wollenberg.   

Abstract

Head and neck squamous cell carcinoma is one of the most frequent cancers and standard treatment has only marginally improved the 5-year survival rate of patients with this disease in the last few decades. It is supposed that cytokine alterations in immune, inflammatory and angiogenetic regulatory routes within the head and neck squamous cell carcinoma microenvironment play a critical role in tumor aggressiveness, its response to chemo- and radiation therapies, as well as the development of immune escape mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17020454     DOI: 10.1586/14737140.6.9.1195

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  20 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

2.  The G protein-coupled receptor GALR2 promotes angiogenesis in head and neck cancer.

Authors:  Rajat Banerjee; Elizabeth A Van Tubergen; Christina S Scanlon; Robert Vander Broek; Joel P Lints; Min Liu; Nickole Russo; Ronald C Inglehart; Yugang Wang; Peter J Polverini; Keith L Kirkwood; Nisha J D'Silva
Journal:  Mol Cancer Ther       Date:  2014-02-25       Impact factor: 6.261

3.  RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression.

Authors:  Tamaki Yamada; Masumi Tsuda; Tomomi Takahashi; Yasunori Totsuka; Masanobu Shindoh; Yusuke Ohba
Journal:  Am J Pathol       Date:  2011-05-10       Impact factor: 4.307

4.  Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma.

Authors:  Elizabeth Van Tubergen; Robert Vander Broek; Julia Lee; Gregory Wolf; Thomas Carey; Carol Bradford; Mark Prince; Keith L Kirkwood; Nisha J D'Silva
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

Review 5.  Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer.

Authors:  Charles C L Tong; Johnny Kao; Andrew G Sikora
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

Review 6.  Current and potential inflammation targeted therapies in head and neck cancer.

Authors:  Frederick Wang; Pattatheyil Arun; Jay Friedman; Zhong Chen; Carter Van Waes
Journal:  Curr Opin Pharmacol       Date:  2009-06-29       Impact factor: 5.547

7.  Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas.

Authors:  Camilla Rydberg; Anne Månsson; Rolf Uddman; Kristian Riesbeck; Lars-Olaf Cardell
Journal:  Immunology       Date:  2008-12-26       Impact factor: 7.397

8.  Protandim, a fundamentally new antioxidant approach in chemoprevention using mouse two-stage skin carcinogenesis as a model.

Authors:  Jianfeng Liu; Xin Gu; Delira Robbins; Guohong Li; Runhua Shi; Joe M McCord; Yunfeng Zhao
Journal:  PLoS One       Date:  2009-04-22       Impact factor: 3.240

Review 9.  Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer.

Authors:  Ramez Philips; Chihun Han; Brian Swendseid; Joseph Curry; Athanassios Argiris; Adam Luginbuhl; Jennifer Johnson
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

10.  Gα₁₂ drives invasion of oral squamous cell carcinoma through up-regulation of proinflammatory cytokines.

Authors:  Shiou-Ling Jian; Hsin-Yi Hsieh; Chun-Ta Liao; Tzu-Chen Yen; Shu-Wei Nien; Ann-Joy Cheng; Jyh-Lyh Juang
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.